Portfolio

Product: Porphyrin Metabolite Activation (PoMA)
Approach: A drug-led, tumor-selective oncology approach designed to activate 5-ALA–derived protoporphyrin IX (PpIX) with the Alpheus LIDU™ low-intensity defocused ultrasound system.
Strategic Area: Medical Device
Funding Impact: Part of seed round of funding to support first-in-human clinical trial of the company’s proprietary, non-invasive drug-device therapy system for recurrent high-grade gliomas

Product: Focused Ultrasound System
Approach: Enables precision medicine for brain tumors accomplished by transient and reversible opening the blood-brain barrier (BBB), which can improve patient outcomes by accelerating drug approvals, and enabling liquid biopsy (blood) tests, providing a real-time view of the disease biology.
Strategic Area: Medical Device
Funding Impact: Preclinical development of device to enable preclinical safety studies and planning for first human clinical studies

Product: EnTrega CNS Drug Delivery System
Approach: EnTrega is a novel system engineered by EnClear to deliver therapies into the cerebrospinal fluid (CSF), and via proprietary software, optimize therapeutic residence time and drug distribution, potentially improving outcomes in a variety of CNS diseases, including brain tumors. The system will feature non-invasive patient monitoring, machine learning-enhanced safety protocols, and automated CSF sampling. 
Strategic Area: Medical Device
Funding Impact: To support pre-clinical development of EnTrega.

Product: 3D-Predict™Glioma
Approach: 3D-Predict™ Glioma test accurately predicts responders and non-responders to standard of care treatments, and can help inform therapy selection in the clinic for glioblastoma (GBM) and other high-grade glioma patients.
Strategic Area: Advanced Diagnostics 
Funding Impact: To support further commercialization and adoption of 3D-Predict™Glioma

Product: SurVaxM
Approach: A first-in-class immunotherapy that targets survivin, a cell-survival protein. SurVaxM stimulates a patients’ own immune response to control tumor growth and prevent future disease recurrence. SurVaxM is currently being evaluated as a potential treatment for newly diagnosed glioblastoma (GBM) in clinical trials, and may ultimately be tested for efficacy in other tumor types. 
Strategic Area: Immunotherapy – Vaccine
Funding Impact: To support an ongoing phase 2b clinical study of SurVaxM in patients with newly diagnosed GBM, as well as subsequent registration-related work to prepare the company for potential commercialization of this therapy. 

Product: KL-50
Approach: Developing novel agents that could benefit patients with temozolomide resistant, MGMT mutant GBM, and potential other tumor types
Strategic Area: DNA Damage Response
Funding Impact: Preclinical development of lead candidate KL-50 and additional analogs

Status: Successful exit, upon acquisition by Merck in October 2024

Product: TSM1001
Approach: Telo Therapeutics is developing an orally bioavailable, highly CNS-penetrant lead small molecule that is well positioned to become a best in class inhibitor of XPO1, a clinically validated but under-exploited oncology target.
Strategic Area: Precision Oncology
Funding Impact: Supporting preclinical evaluation of XPO1 targeted therapies

Product: TGX-007
Approach: Trogenix is a University of Edinburgh spinout developing a differentiated gene therapy (TGX-007) designed to deliver personalized immunotherapy for GBM patients. This asset is the result of research by Steven Pollard, PhD, a world-renowned glioblastoma (GBM) and gene therapy expert. The Trogenix platform is expected to have broad applicability across oncology and regenerative medicine.
Strategic Area: Immunotherapy – Gene Therapy
Funding Impact: To support IND-enabling work in preparation for first in human studies

Product: Dubodencel (DOC1021)
Approach: Diakonos Oncology Corp. is a clinical-stage biotechnology company dedicated to revolutionizing cancer immunotherapy with its proprietary double-loaded, patient-derived dendritic cell therapeutic platform focused on addressing the critical, unmet medical need for treatment of late-state and aggressive cancers like GBM.
Strategic Area: Immunotherapy – Dendritic Cell Vaccine
Funding Impact: To accelerate the company’s Phase 2 glioblastoma trial for dubodencel

Product: ALTX-100 / CAR-TEAM platform
Approach: A novel T cell-based immunotherapy platform, CAR-TEAM, with a dual mechanism approach built to reach and engage difficult-to-treat solid tumors, like glioblastoma. It’s lead candidate, ALTX-100, is an autologous, tumor-specific CAR-T cell therapy using a vector that codes for a secreted bi-specific T cell engager, which targets EGFRvIII, the most common EGFR mutation in glioblastoma.
Strategic Area: Immunotherapy – CAR-T cell therapy
Funding Impact: To support further clinical development and evaluation of ALTX-100